Erika P. Hamilton, MD
The end of 2018 brought intriguing data in the HER2-positive breast cancer space, specifically with updates in adjuvant treatment and the duration of trastuzumab (Herceptin) therapy, as well as a nod toward emerging potential options in the metastatic setting, explained Erika P. Hamilton, MD.
State of the Science Summit™ on Breast Cancer, Hamilton, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, reflected on the latest data in HER2-positive breast cancer and additional therapies moving through the pipeline.
OncLive®: What are the most recent findings in HER2-positive breast cancer?
: There are 2 big categories in HER2-positive breast cancer right now. The first is optimal duration of therapy. There have been some recent abstracts with the HERA, PERSEPHONE, and PHARE trials, which were studies that tried to define the most beneficial length of trastuzumab. We have learned that 2 years [of trastuzumab] is not better than 1 year, and the 6-month story is a little bit debatable.
... to read the full story